Galectin Therapeutic GALT

$3.90 +0.14 (3.72%)

Valuation

Market cap
247,622,000
Revenue TTM
$0
Net income TTM
$-30,840,000
PE ratio
0.00
Forward PE
—
Profit margin
0.00%
Debt to equity
-0.76

Trading

Volume
220,500
Avg volume
330,570
Day's range
$3.75 – $3.94
Shares out
65,857,000
Stochastic %K
39%
Beta
0.38
Analysts
Sell
Price target
$11.00

Price

Company profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hyperte...

Show more

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension. It has a joint venture co-owned by SBH Sciences, Inc. to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Industry
Biotechnology
Sector
Healthcare
Phone
678 620 3186
Website
https://galectintherapeutics.com
Address
4960 Peachtree Industrial Boulevard, Suite 240, Norcross, United States

Latest news

Stocktwits

ThomasLD Oct 3, 10:52 PM
$GALT As of September 2026, see how shares have insiders owned (see below) and I am sure that I will have a good time to watch Paris By Night show in Las Vegas in December 12th, 2026. Follow excellent science and big money from all insiders >>>> 50%. Our CoB has owned most of the shares at this time. Good news may be announced next week! GLTA!
0 replies
dwpro Oct 3, 8:29 PM
$GALT What will Monday morning bring??
1 replies
Manonfire8 Oct 3, 8:14 PM
$GALT the filing and balance sheet clean up are so bullish, clear indication there are active M&A discussions occurring. I need to get more dry powder together and up my shares.
0 replies
coba4444 Oct 3, 7:47 PM
$GALT I appreciate the explanation. Seems logical.
0 replies
SNOWBALLDB321 Oct 3, 4:33 PM
$GALT The GALT share expansion shareholder vote is in Decenber followed by the JP Morgan health care conference in January where major buyouts, partnerships, and licensing agreements are heavily discussed, initiated, and occasionally announced. 💡 How Dealmaking Works at JPM • The "Super Bowl": It serves as the world's largest healthcare investment gathering, acting as an unofficial kickoff for annual deal season. • Hallway Chatter: Many official agreements are preceded by private suite meetings and handshake negotiations during the event. • Timing Variations: While some licensing deals or smaller acquisitions drop during the conference week, massive multi-billion-dollar buyouts are often timed just before, during, or finalized weeks after the event. • Networking Hub: Executives use the massive San Francisco gathering for face-to-face speed dating between biotech innovators and big pharma acquirers.
0 replies
coba4444 Oct 3, 3:49 PM
$GALT ok I see that but now I am concerned after 2 dilution events. Is this a normal procedure/process in the event of partnership? Why do existing shareholders have to accept all of the burden for this potential partnership? The only caveat is that DU and the rest of the team also have accept the dilution, except they receive warrants and RSU for their part. We have this wonderful drug, why are the existing shareholders having to carry the load?
2 replies
Indibviduate1 Oct 3, 3:39 PM 0 replies
coba4444 Oct 3, 3:35 PM
$GALT How can this continued dilution be healthy for any current stockholder? From cloud AI: But here is the part I would focus on as an investor The company states: "We do not have any present plan, arrangement or understanding to designate and issue any of the shares..." That means: No announced partnership. No disclosed deal. No identified buyer. -No announced financing. at least according to the proxy. My interpretation The filing reads more like: Uihlein converted debt into stock, consuming a lot of authorized shares. Management wants enough shares for employee equity plans, warrants, acquisitions, an other corporate uses. turn6search41 The proxy does not read to me as "we have a partnership and need shares for it." it reads as "we need a larger share pool because the company may need financing and/or a strategic partner in the future. One bullish item I noticed is that converted over $105 million of debt into equity rather than demanding repayment, highly dilutive to existing shareholders.
1 replies